BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 22028323)

  • 1. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
    Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
    J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
    Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
    Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
    Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
    J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
    Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
    Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
    Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
    Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4.
    Ueda N; Kuki H; Kamimura D; Sawa S; Seino K; Tashiro T; Fushuku K; Taniguchi M; Hirano T; Murakami M
    Int Immunol; 2006 Sep; 18(9):1397-404. PubMed ID: 16914507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
    Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
    Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant NKT cells preferentially modulate the function of CD8 alpha+ dendritic cell subset in inducing type 1 immunity against infection.
    Joyee AG; Uzonna J; Yang X
    J Immunol; 2010 Feb; 184(4):2095-106. PubMed ID: 20089704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin.
    Gorbachev AV; Fairchild RL
    Eur J Immunol; 2006 Sep; 36(9):2494-503. PubMed ID: 16909435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression.
    Zeng J; Shahbazi M; Wu C; Toh HC; Wang S
    J Immunol; 2012 May; 188(9):4297-304. PubMed ID: 22407918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.
    Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH
    Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.